Investor Sues $2.6B Allergy Drugmaker Over Nestle Deal

Law360 (September 25, 2020, 5:42 PM EDT) -- An investor in a $2.6 billion biopharmaceutical company that's making the first federally approved peanut allergy treatment for children alleged that the company left out key financial information in disclosures surrounding its planned sale to Nestle, contending in a New York federal court complaint that the omission makes it impossible for shareholders to properly weigh the deal.

Aimmune Therapeutics Inc. investor Kenneth Davis on Wednesday accused the company and its board of recommending Nestle's offer to buy out all of the allergy treatment makers' shareholders although the deal "would prevent current Aimmune shareholders from participating in Aimmune's strong growth prospects," according...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!